The Clinical Evaluation Of Weiwei I Granule On Spleen Deficiency Chronic Atrophic Gastritis

Objective:Through evaluating the clinical curative effect of Atrophy I granule on spleen deficiency CAG(chronic atrophic gastritis), may be we can provide theoretical basis for standardized CAG treatment of traditional Chinese medicine.Method:The study chose101patients who were consistent with the clinical diagnosis of spleen insufficiency chronic atrophic gastritis from6research centers to enroll the randomized, parallel, double-blind and double-dummy clinical research, and put the Vitacoenzyme Tablets as control medicine. From the symptom score, symptomatic efficacy, endoscopy findings and pathologic analysis of the results aspects, we can evaluate the clinical efficacy of Atrophy1granule to spleen deficiency CAG.Results:The clinical improvement rate of Atrophy I group was over70,but Vitacoenzyme group’s was less than70and over30.The total cure rate of Atrophy I group was87.1,and Vitacoenzyme group’s was56.41. There were statistical differences between the two groups at clinical effective. The reduce rate of gastroscopic mucosa atrophy score and pathological atrophy level of Atrophy I group were26.58and35.48,and Vitacoenzyme group’s were22.64、21.31.There were no statistical differences between the two groups at atrophy of gastric mucosa.Conclusion:Atrophy1granule can obviously improve the clinical symtoms of spleen deficiency CAG, and also is somewhat effective in treating the atrophy of gastric mucosa. Atrophy1granule has a certain point unique advantage than Vitacoenzyme Tablets on spleen deficiency CAG. As a result, Atrophy I granule has good practical and promotion value.